All News
Filter News
Found 808,690 articles
-
Sorrento and Celularity to Initiate Emergency Allogeneic Natural Killer (NK) Cell Therapy Development for Coronavirus Infection
1/29/2020
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced it has initated a clinical and manufacturing collaboration with Celularity, Inc., a Warren, New Jersey, based clinical-stage cell therapeutics company delivering transformative allogeneic cellular therapies derived from the postpartum human placenta
-
InMode to Participate in IMCAS World Congress in Paris
1/29/2020
InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, will participate in the IMCAS World Congress, one of the largest European meetings of plastic and aesthetic surgeons, which will take place in Paris, France from January 30 - February 1, 2020.
-
Trillium Closes US$117 Million Public Offering of Common Shares and Series II Non-Voting Convertible First Preferred Shares
1/29/2020
Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the closing of its previously announced underwritten public offering of 41,279,090 common shares of the Company and 1,250,000 Series II Non-Voting Convertible First Preferred Shares of the Company (the “Offering”
-
Verrica Pharmaceuticals Announces the Hiring of Two Vice Presidents to Further Grow its Commercial Capabilities
1/29/2020
Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for viral skin diseases requiring medical interventions, today announced the appointment of two new Vice Presidents in its Commercial Operations group to support the potential launch, if approved, of YCANTH™ (cantharidin 0.7% topical solution),
-
Healogics Supports 2020 American Diabetes Association Compendium
1/29/2020
Healogics® Inc., the nation's largest provider of advanced wound care services, announced their support of a new publication from the American Diabetes Association (ADA): Diagnosis and Management of Diabetic Foot Infections.
-
Infinitus donates 6 million yuan in cash and supplies to support prevention and treatment efforts in dealing with 2019-nCoV
1/29/2020
In the last few days, all attention in China is focused on the prevention and treatment of the pneumonia caused by the novel coronavirus (2019-nCoV).
-
TELA Bio Announces Appointment of New Chief Commercial Officer
1/29/2020
TELA Bio, Inc. (“TELA”) (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announces the appointment of Peter Murphy to the newly created role of Chief Commercial Officer.
-
Johnson & Johnson Launches Multi-Pronged Response to Coronavirus Global Public Health Threat
1/29/2020
Johnson & Johnson (NYSE: JNJ) today announced that it is mobilizing resources at its Janssen Pharmaceutical Companies to launch a multi-pronged response to the novel coronavirus (also known as 2019-nCoV or Wuhan coronavirus) outbreak.
-
DelMar Pharmaceuticals Announces Peer-Reviewed Publication of Interim Results of Phase 2 Clinical Trial of VAL-083 As First-Line Treatment in Newly-Diagnosed MGMT-Unmethylated Glioblastoma Multiforme
1/29/2020
DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced the publication of previously released interim clinical data in the February 2020 issue of peer-reviewed journal, Glioma.
-
Unum Therapeutics Provides Updates to its Phase 1 Trial of ACTR707 for HER2+ Solid Tumor Cancers
1/29/2020
Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on developing curative cell therapies for cancer, today announced it has completed Cohort 1 enrollment with no dose-limiting toxiticies (DLT) observed in the ATTCK-34-01 Phase 1 trial evaluating Unum’s novel Antibody-Coupled T cell Receptor investigational therapy, ACTR707,
-
Lilly Receives FDA Priority Review for the Selpercatinib New Drug Application
1/29/2020
Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has granted priority review for the New Drug Application (NDA) for selpercatinib (LOXO-292), for the treatment of patients with advanced RET fusion-positive non-small cell lung cancer (NSCLC)
-
Purdue-Affiliated Health Technology Company, physIQ, Receives $500,000 to Advance AI Innovations
1/29/2020
A Purdue University–affiliated company using artificial intelligence to improve health care delivery has received a $500,000 investment from Purdue Research Foundation’s Foundry Investment Fund to help them advance medical technology.
-
Trovagene Receives Approximately $1.45 Million From Exercise of Warrants
1/29/2020
Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis) for the treatment of various cancers including prostate, colorectal and leukemia, announced today that it has received approximately $1.45 million in proceeds from holders exercising common stock purchase warrants at an exercise price of $1.56 per share.
-
ASHG Survey Finds Americans Strongly Support Human Genetics Research & Potential
1/29/2020
Respondents Want Confidence in Data Privacy, Have Some Knowledge Gaps
-
Orchard Therapeutics Announces FDA Granted Orphan Drug Designation for OTL-102 for the Treatment of X-linked Chronic Granulomatous Disease (X-CGD)
1/29/2020
Early Clinical Data Support ex vivo Hematopoietic Stem Cell Gene Therapy as a Potentially Promising Treatment Option for X-CGD
-
CORRECTING and REPLACING Nobel Laureate Leads MedTech Startups Addressing China’s Deadly Virus at OurCrowd Global Investor Summit
1/29/2020
Eyal Gura, Co-Founder and chairman of Zebra Medical Vision, which has secured 4 FDA clearances for its AI-powered imaging analytics platform.
-
Eastern New Mexico Medical Center's Dr. Tom Wulf honored as Alteon Health Facility Medical Director of the Year
1/29/2020
Thomas Wulf, MD, Director of the Emergency Department at Eastern New Mexico Medical Center, was recently selected as one of three 2019 Facility Medical Directors of the Year by Alteon Health, the industry-leading national medical group that has managed the hospital's Emergency Medicine program since 2011.
-
UH Portage Medical Center's Dr. Frank Kelley honored as Alteon Health Facility Medical Director of the Year
1/29/2020
Frank Kelley, MD, Director of Hospital Medicine at University Hospitals Portage Medical Center, was recently selected as one of three 2019 Facility Medical Directors of the Year by Alteon Health, the industry-leading national medical group that has managed Portage's Hospitalist program since 2006.
-
Equillium to Present Translational Preclinical Data Demonstrating Increased Survival & Decreased Disease Severity in Models of Graft-Versus-Host Disease Treated with Itolizumab at the Transplantation & Cellular Therapy Meetings of ASTCT & CIBMTR
1/29/2020
Equillium, Inc. announced that translational data supporting the potential of itolizumab in the treatment of graft-versus-host disease will be presented at the Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy and the Center for International Blood & Marrow Transplant Research being held February 19-23, 2020 at the World Center Marriott in Orlando, Florida.
-
Albireo Announces Proposed Public Offering of Common Stock - Jan. 29, 2020
1/29/2020
Albireo Pharma, Inc., a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced that it has commenced a proposed underwritten public offering of its common stock.